{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T12:56:52Z","timestamp":1777294612101,"version":"3.51.4"},"reference-count":35,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology Retina"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.oret.2018.09.003","type":"journal-article","created":{"date-parts":[[2018,9,15]],"date-time":"2018-09-15T21:00:48Z","timestamp":1537045248000},"page":"154-160","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"title":["Mineralocorticoid Receptor Antagonists in Central Serous Chorioretinopathy"],"prefix":"10.1016","volume":"3","author":[{"given":"Sean K.","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1651-8512","authenticated-orcid":false,"given":"Rachel M.","family":"Tandias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2693-9046","authenticated-orcid":false,"given":"Brendan K.","family":"Seto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge G.","family":"Arroyo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.oret.2018.09.003_bib1","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1038\/eye.2010.130","article-title":"Central serous chorioretinopathy: an update on pathogenesis and treatment","volume":"24","author":"Gemenetzi","year":"2010","journal-title":"Eye"},{"key":"10.1016\/j.oret.2018.09.003_bib2","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1097\/IAE.0000000000001443","article-title":"Acute central serous chorioretinopathy","volume":"37","author":"Daruich","year":"2017","journal-title":"Retina"},{"key":"10.1016\/j.oret.2018.09.003_bib3","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ophtha.2007.02.032","article-title":"The incidence of central serous chorioretinopathy in Olmsted County, Minnesota, 1980\u20132002","volume":"115","author":"Kitzmann","year":"2008","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2018.09.003_bib4","first-page":"270","article-title":"Visual prognosis in central serous choroidopathy: residual Amsler grid changes","volume":"26","author":"Jalali","year":"1991","journal-title":"Can J Ophthalmol"},{"key":"10.1016\/j.oret.2018.09.003_bib5","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1097\/APO.0b013e31826fdfd4","article-title":"An update on the diagnosis and management of central serous chorioretinopathy","volume":"1","author":"Liu","year":"2012","journal-title":"Asia-Pacific J Ophthalmol"},{"key":"10.1016\/j.oret.2018.09.003_bib6","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s40135-017-0133-4","article-title":"Diagnosed a patient with central serous chorioretinopathy? Now what? Management of central serous chorioretinopathy","volume":"5","author":"Goldhagen","year":"2017","journal-title":"Curr Ophthalmol Rep"},{"key":"10.1016\/j.oret.2018.09.003_bib7","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1136\/bjophthalmol-2016-309247","article-title":"Preferred practice pattern in central serous chorioretinopathy","volume":"101","author":"Mehta","year":"2017","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.oret.2018.09.003_bib8","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ajo.2016.07.026","article-title":"A\u00a0multicenter study on the long-term outcomes of half-dose photodynamic therapy in chronic central serous chorioretinopathy","volume":"170","author":"Lai","year":"2016","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.oret.2018.09.003_bib9","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1136\/bjo.72.11.829","article-title":"Long-term follow-up of a prospective trial of argon laser photocoagulation in the treatment of central serous retinopathy","volume":"72","author":"Ficker","year":"1988","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.oret.2018.09.003_bib10","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.2147\/OPTH.S87499","article-title":"Subthreshold micropulse yellow laser treatment for nonresolving central serous chorioretinopathy","volume":"9","author":"Abd Elhamid","year":"2015","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.oret.2018.09.003_bib11","doi-asserted-by":"crossref","first-page":"837","DOI":"10.3928\/23258160-20150909-08","article-title":"Randomized clinical trial to compare micropulse photocoagulation versus half-dose verteporfin photodynamic therapy in the treatment of central serous chorioretinopathy","volume":"46","author":"Kretz","year":"2015","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"10.1016\/j.oret.2018.09.003_bib12","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1097\/IAE.0000000000000655","article-title":"Outcomes of treatment of choroidal neovascularization associated with central serous chorioretinopathy with intravitreal antiangiogenic agents","volume":"35","author":"Chhablani","year":"2015","journal-title":"Retina"},{"key":"10.1016\/j.oret.2018.09.003_bib13","doi-asserted-by":"crossref","first-page":"3405","DOI":"10.1096\/fj.09-154344","article-title":"The neuroretina is a novel mineralocorticoid target: aldosterone upregulates ion and water channels in M\u00fcller glial cells","volume":"24","author":"Zhao","year":"2010","journal-title":"FASEB J"},{"key":"10.1016\/j.oret.2018.09.003_bib14","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1172\/JCI61427","article-title":"Mineralocorticoid receptor is involved in rat and human ocular chorioretinopathy","volume":"122","author":"Zhao","year":"2012","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.oret.2018.09.003_bib15","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1136\/bjo.81.11.962","article-title":"Endogenous cortisol profile in patients with central serous chorioretinopathy","volume":"81","author":"Garg","year":"1997","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.oret.2018.09.003_bib16","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1001\/jamaophthalmol.2017.0245","article-title":"Association of a haplotype in the NR3C2 gene, encoding the mineralocorticoid receptor, with chronic central serous chorioretinopathy","volume":"135","author":"van Dijk","year":"2017","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.oret.2018.09.003_bib17","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1080\/08820538.2016.1228418","article-title":"Systemic Mineralocorticoid Antagonists in the Treatment of Central Serous Chorioretinopathy","volume":"32","author":"Yang","year":"2017","journal-title":"Semin Ophthalmol"},{"key":"10.1016\/j.oret.2018.09.003_bib18","doi-asserted-by":"crossref","first-page":"439","DOI":"10.3928\/23258160-20150422-06","article-title":"Oral eplerenone for treatment of chronic central serous chorioretinopathy: a case series","volume":"46","author":"Salz","year":"2015","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"10.1016\/j.oret.2018.09.003_bib19","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s00417-016-3436-5","article-title":"Long-term results and recurrence rates after spironolactone treatment in non-resolving central serous chorio-retinopathy (CSCR)","volume":"255","author":"Herold","year":"2017","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.oret.2018.09.003_bib20","doi-asserted-by":"crossref","first-page":"e610","DOI":"10.1111\/aos.13491","article-title":"Eplerenone for chronic central serous chorioretinopathy-a randomized controlled prospective study","volume":"95","author":"Schwartz","year":"2017","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.oret.2018.09.003_bib21","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1097\/IAE.0000000000000748","article-title":"Central serous chorioretinopathy treated with mineralocorticoid antagonists: a one-year pilot study","volume":"36","author":"Ghadiali","year":"2016","journal-title":"Retina"},{"key":"10.1016\/j.oret.2018.09.003_bib22","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1007\/s10792-016-0377-2","article-title":"Comparison of two mineralcorticosteroids receptor antagonists for the treatment of central serous chorioretinopathy","volume":"37","author":"Pichi","year":"2016","journal-title":"Int Ophthalmol"},{"key":"10.1016\/j.oret.2018.09.003_bib23","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1136\/bjophthalmol-2017-311096","article-title":"Spironolactone versus observation in the treatment of acute central serous chorioretinopathy","volume":"102","author":"Sun","year":"2018","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.oret.2018.09.003_bib24","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1097\/IAE.0000000000001649","article-title":"A\u00a0randomized double-blind placebo-control pilot study of eplerenone for the treatment of central serous chorioretinopathy (ecselsior)","volume":"38","author":"Rahimy","year":"2018","journal-title":"Retina"},{"key":"10.1016\/j.oret.2018.09.003_bib25","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1097\/IAE.0000000000000614","article-title":"Spironolactone for nonresolving central serous chorioretinopathy: a randomized controlled crossover study","volume":"35","author":"Bousquet","year":"2015","journal-title":"Retina"},{"key":"10.1016\/j.oret.2018.09.003_bib26","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/S0002-9394(02)01825-1","article-title":"A\u00a0computerized method of visual acuity testing: adaptation of the early treatment of diabetic retinopathy study testing protocol","volume":"135","author":"Beck","year":"2003","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.oret.2018.09.003_bib27","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.oret.2018.09.003_bib28","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1136\/bmj.333.7568.597","article-title":"The case of the misleading funnel plot","volume":"333","author":"Lau","year":"2006","journal-title":"BMJ"},{"key":"10.1016\/j.oret.2018.09.003_bib29","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.preteyeres.2015.05.003","article-title":"Central serous chorioretinopathy: recent findings and new physiopathology hypothesis","volume":"48","author":"Daruich","year":"2015","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.oret.2018.09.003_bib30","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1124\/dmd.31.11.1448","article-title":"Pharmacokinetics and metabolism of [14C]eplerenone after oral administration to humans","volume":"31","author":"Cook","year":"2003","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.oret.2018.09.003_bib31","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1159\/000444058","article-title":"Mineralocorticoid antagonists in the treatment of central serous chorioretinopathy: a comparative analysis","volume":"56","author":"Kapoor","year":"2016","journal-title":"Ophthalmic Res"},{"key":"10.1016\/j.oret.2018.09.003_bib32","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/j.ophtha.2018.04.021","article-title":"Half-dose photodynamic therapy versus high-density subthreshold micropulse laser treatment in patients with chronic central serous chorioretinopathy","volume":"125","author":"van Dijk","year":"2018","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2018.09.003_bib33","first-page":"1","article-title":"Comparison of short-term efficacy between oral spironolactone treatment and photodynamic therapy for the treatment of nonresolving central serous chorioretinopathy","author":"Lee","year":"2017","journal-title":"Retina"},{"key":"10.1016\/j.oret.2018.09.003_bib34","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1002\/clc.22025","article-title":"Aldosterone receptor antagonists in cardiovascular disease: a review of the recent literature and insight into potential future indications","volume":"35","author":"Markowitz","year":"2012","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.oret.2018.09.003_bib35","doi-asserted-by":"crossref","first-page":"672","DOI":"10.4065\/84.8.672","article-title":"Male gynecomastia","volume":"84","author":"Haynes","year":"2009","journal-title":"Mayo Clin Proc"}],"container-title":["Ophthalmology Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468653018303622?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468653018303622?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T09:25:19Z","timestamp":1762853119000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468653018303622"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["S2468653018303622"],"URL":"https:\/\/doi.org\/10.1016\/j.oret.2018.09.003","relation":{},"ISSN":["2468-6530"],"issn-type":[{"value":"2468-6530","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mineralocorticoid Receptor Antagonists in Central Serous Chorioretinopathy","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology Retina","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.oret.2018.09.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 by the American Academy of Ophthalmology","name":"copyright","label":"Copyright"}]}}